Avalia lmmunotherapies' first vaccine product is a cancer vaccine to treat patients suffering from HPV associated cancers. Its vaccine approach has the potential to induce patient responses against HPV cancers that are not currently responsive to checkpoint immunotherapy.
Every day in the US, about 12,000 people ages 15 to 24 are infected with the human papillomavirus (HPV). Of those, 2,600 are infected with the HPV16 strain, which is responsible for 50% of human cervical cancers and more than 85% of HPV-positive head & neck, anal and anal-genital cancers. In the US, only 31% of teenagers are fully inoculated with the preventative vaccines, Gardasil and Cervirax. These preventative vaccines cannot cure established HPV infections and standard of care treatments cannot eliminate HPV outside the treated area. This unmet need will be satisfied with Avalia's vaccine product.
